Modipafant, a new PAF antagonist: Pharmacokinetics and disposition in rat, dog and man

Xenobiotica

Volumn 26, Issue 9, 1996, Pages 963-975

  Jezequel, S G ^a   Uden, S ^a   Wastall, P ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FECES; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RAT; SEX DIFFERENCE;

ANIMALIA; CANIS FAMILIARIS;

EID: 0029852735     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.3109/00498259609052498     Document Type: Article

References (24)

1. ALABASTER, V. A., KEIR, R. F., PARRY, M. J., and DE SOUZA, R. N., 1991, UK-74,505: a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. In New Drugs for Asthma Therapy edited by G. P. Anderson, S. D. Chapman, and J. Morley. Agents and Action, 34 (suppl.), pp. 221-227.
2. BERESFORD, A. P., MACRAE, P. V., and STOPHER, D. A., 1988, Metabolism of amlodipine in the rat and dog: a species difference, Xenobiotica, 18, 169-182.
3. BRAQUET, P., TOUQUI, L., SHEN, T. Y., and VARGAFTIG, B. B., 1987, Perspectives in platelet-activating factor research. Pharmacological Reviews, 39, 97-145.
4. COOPER, K., FRAY, M. J., RICHARDSON, K., and STEELE, J., 1990, A novel and highly potent dihydropyridine PAF antagonist: synthesis and structure activity relationship. Journal Lipid Mediators, 2, 212-218.
5. COOPER, K., FRAY, M. J., PARRY, M. J., RICHARDSON, K., and STEELE, J., 1992, 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure activity relationships of 2-(4-heterocyclyl) phenyl derivatives. Journal of Medicinal Chemistry, 35, 3115-3129.
6. DAYTON, P. G., ISRAEILE, Z. H., and HENDERSON, J. D., 1983, Elimination of drugs by passive diffusion from blood to intestinal lumen : factors influencing non-biliary secretion by the biliary tract. Drug Metabolism Reviews, 14, 1193-1206.
7. DEMOPOULOS, C. A., PINCKARD, R. N., and HANAHAN, D. J., 1979, Platelet-activating factor, evidence for 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine as the active component (a new class of lipid mediators), Journal Biological Chemistry, 254, 9350-9358.
8. HELANDER, H. F., RAMSAY, C. H., and REGAND, C. G., 1985, Localisation of omeprazole and metabolites in the mouse. Scandinavian Journal of Gastroenterology, 20 (suppl 108), 95-104.
9. HUMPHREY, M. J., JEVONS, S., and TARBIT, M. H., 1985, Pharmacokinetic evaluation of UK-49,858. A metabolically stable triazole antifungal drug, in animals and man. Antimicrobial Agents and Chemotherapy, 28, 648-653.
10. KOBLIAKOV, V., POPOVA, N., and ROSSIE, L., 1991, Regulation of the expression of the sex specific isoforms of cytochrome P-450 in rat liver. European Journal of Biochemistry, 195, 585-591.
11. KOLTAI, M., HOSFORD, D., GUINOT, P., ESANU, A., and BRAQUET, P., 1991a, Platelet activating factor (PAF). A review of its effects, antagonists and possible future clinical applications (Part I). Drugs, 42, 9-29.
12. KOLTAI, M., HOSFORD, D., GUINOT, P., ESANU, A., and BRAQUET, P., 1991b, Platelet activating factor (PAF). A review of its effects, antagonists and possible future clinical applications (Part II). Drugs, 42, 174-204.
13. KUITERT, L. M., HUI, K. P., UTHAYARKUMAR, S., BUNK, W., NEWLAND, A. C., UDEN, S., and BARNES, N. C., 1993, Effect of the platelet-activating factor antagonist UK-74,505 on early and late response to allergen. American Review of Respiratory Diseases, 147, 82-86.
14. KUITERT, L. M., ANGUS, R. M., BARNES, N. C., BARNES, P. J., BONE, M. F., CHUNG, K. F., FAIRFAX, A. J., HIGENBOTHAM, T. W., CONNOR, B. J., PIOTROSKA, B., ROGNIECKI, J., UDEN, S., WALTER, E. H. and WILLARD, C. J., 1995, Effect of a novel potent platelet activating factor antagonist, Modipafant. American Journal of Respiratory Critical are Medicine, 151, 1331-1335.
15. NIWA, T., TOKUMA, Y., and NOGUCHI, H., 1988, Oxidation of nilvadipine, a new dihydropyridine calcium antagonist, to the corresponding pyridine by rat liver microsomes. Xenobiotica, 18, 217-224.
16. PARRY, M. J., ALABASTER, V. A., CHEESEMAN, H. E., COOPER, K., DE SOUZA, R. N., and KEIR, R. F., 1994, Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity. Journal of Lipid Mediators and Cell Signalling, 10, 251-268.
17. PARRY, M. J., ALABASTER, V. A., CHEESEMAN, H. E., DE SOUZA, R. N., and KIER, R. F., 1990, In vitro and in vivo profile of UK-74,505 : a novel, highly potent and selective dihydropyridine PAF antagonist. Journal of Lipid Mediators and Cell Signalling, 2, 181-186.
18. PATON, W. D. M., and RANG, H. P., 1966, A kinetic approach to mechanism of drug action. Advances in Drug Research 3, 57-80.
19. PONS, F., ROSSI, A. G., NORMAN, K. E., WILLIAMS, T. J., and NOURSHARGH, S., 1993, Role of platelet-activating factor (PAF) in platelet accumulation in rabbit skin : effect of the novel long-acting PAF antagonist, UK-74,505. British Journal Pharmacology, 109, 234-242.
20. RITSCHEL, W. A., ADOLPH, S., and DENSON, D. D., 1990, Ion trapping of meperidine: influence of antacid treatments on serum and gastric fluid concentration. Methods and Findings in Experimental Clinical Pharmacology, 12, 47-51.
21. SMITH, D. A., 1991, Species differences in metabolism and pharmacokinetics; are we close to an understanding? Drug Metabolism Reviews, 23, 355-373.
22. STOPHER, D., and MCCLEAN, S., 1990, An improved method for the determination of distribution coefficients. Journal of Pharmacy and Pharmacology, 42, 144.
23. 3H] nicotine in dogs and rhesus monkeys. Toxicology and Applied Pharmacology, 32, 21-31.
24. YUGE, T., HASE, T., TAKEYANAGI, Y., KAMASUKA, T., AMEMIYA, K., and HORIBA, M., 1984, Pharmacokinetic studies of mabuterol, a new selective beta-2 stimulant, Arzneimittel Forschung, 34, 1659-67.